AstraZeneca (LON:AZN) Price Target Raised to £160

AstraZeneca (LON:AZN) had its target price boosted by Berenberg Bank from £145 to £160 in a research note issued to investors on Tuesday, MarketBeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on AZN. Jefferies Financial Group restated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Citigroup initiated coverage on shares of AstraZeneca in a research note on Tuesday. They set a “buy” rating and a £170 price objective on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Finally, Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of £145.83.

AstraZeneca Stock Performance

AZN opened at £134.60 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The business’s 50 day moving average is £137.62 and its 200-day moving average is £125.66. The stock has a market cap of £208.67 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca has a twelve month low of GBX 9,573.51 and a twelve month high of £144.10.

Insider Buying and Selling at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is currently owned by company insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.